BALAXI PHARMACEUTICALS growth ratios

·UnclassifiedChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−7.7%+21.2%−28.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−77.1%−20.4%−17.3%
−82.0%−20.9%−18.5%
−94.3%+1,150.3%−105.2%
−94.3%+295.7%−105.1%
+8.6%+20.1%+7.8%
+7.5%+15.1%+10.1%
+87.1%−819.3%−19.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹109 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-28.3+21.2-7.7—
EBITDA Growth—-17.3-20.4-77.1—
EBIT Growth—-18.5-20.9-82.0—
Net Income Growth—-105.2+1,150.3-94.3—
EPS Growth—-105.1+295.7-94.3—
Total Assets Growth—+7.8+20.1+8.6—
Total Equity Growth—+10.1+15.1+7.5—
Cash from Operations Growth—-19.9-819.3+87.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.